Nancy Price Mendenhall, MD

This review addresses the rationale and evidence for-and the challenges, cost implications, and future development of-proton therapy as an important part of the treatment strategy in Hodgkin lymphoma.

This review discusses the rationale, history, and current status of proton therapy for prostate cancer-and controversies regarding it.

Breast-conserving therapy maywell be the best-studied therapyin all of medicine, with dataavailable from seven mature prospectiverandomized trials that comparedoutcomes with the “gold standard” ofablative mastectomy, as well as datafrom specific programs across thecountry and globe, reflecting a broadrange of clinical and technical skillsand philosophic and technical variationson the theme of breast-conservingtherapy. However, relatively littlehas been published on the late effectsof this therapy. Frassica et al havedone an excellent job of producing adescriptive catalog of the majority ofpotential late effects in patients whosurvive breast-conserving therapy,complete with suggestions regardingmanagement.